Francesca Motta1,2, Andrea Pederzani1, Maria Cristina Carena3, Angela Ceribelli1, Paul B Wordsworth4, Maria De Santis1, Carlo Selmi1,2, Matteo Vecellio5,6. 1. Division of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. 3. Leukocyte Biology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 4. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 5. Division of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. matteo.vecellio@ndorms.ox.ac.uk. 6. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. matteo.vecellio@ndorms.ox.ac.uk.
Abstract
PURPOSE OF REVIEW: To highlight the recent discoveries and lines of evidence on the role of microRNAs in ankylosing spondylitis (AS) and psoriatic arthritis (PsA), focusing on their expression profiling and mechanisms of action. RECENT FINDINGS: AS and PsA are chronic inflammatory musculoskeletal diseases with axial manifestations and represent an excellent model for studying microRNAs contribution to the disease pathogenesis, particularly through immunomodulation, inflammation, and bone remodelling, or their value as candidate diagnostic and prognostic biomarkers. MicroRNAs are single-stranded nucleotides able to regulate gene expression. They are a key component of the epigenetic machinery, involved in physiological and pathological processes. The contribution of microRNAs in AS and PsA (such as miR-29a in regulating bone metabolism) is highlighted by several works in the field but their utility as possible markers must be still confirmed, particularly in larger patients' cohorts.
PURPOSE OF REVIEW: To highlight the recent discoveries and lines of evidence on the role of microRNAs in ankylosing spondylitis (AS) and psoriatic arthritis (PsA), focusing on their expression profiling and mechanisms of action. RECENT FINDINGS:AS and PsA are chronic inflammatory musculoskeletal diseases with axial manifestations and represent an excellent model for studying microRNAs contribution to the disease pathogenesis, particularly through immunomodulation, inflammation, and bone remodelling, or their value as candidate diagnostic and prognostic biomarkers. MicroRNAs are single-stranded nucleotides able to regulate gene expression. They are a key component of the epigenetic machinery, involved in physiological and pathological processes. The contribution of microRNAs in AS and PsA (such asmiR-29a in regulating bone metabolism) is highlighted by several works in the field but their utility as possible markers must be still confirmed, particularly in larger patients' cohorts.
Authors: Désirée van der Heijde; Sofia Ramiro; Robert Landewé; Xenofon Baraliakos; Filip Van den Bosch; Alexandre Sepriano; Andrea Regel; Adrian Ciurea; Hanne Dagfinrud; Maxime Dougados; Floris van Gaalen; Pál Géher; Irene van der Horst-Bruinsma; Robert D Inman; Merryn Jongkees; Uta Kiltz; Tore K Kvien; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compàn; Salih Ozgocmen; Fernando M Pimentel-Santos; John Reveille; Martin Rudwaleit; Jochen Sieper; Percival Sampaio-Barros; Dieter Wiek; Jürgen Braun Journal: Ann Rheum Dis Date: 2017-01-13 Impact factor: 19.103
Authors: Janneke J de Winter; Leonieke J van Mens; Désirée van der Heijde; Robert Landewé; Dominique L Baeten Journal: Arthritis Res Ther Date: 2016-09-01 Impact factor: 5.156